Literature DB >> 11302829

Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis.

C Schmitt1, Y Perel, J L Harousseau, S Lemerle, E Chwetzoff, J P le Moing, J C Levron.   

Abstract

We investigated the pharmacokinetics and safety of an oral solution of itraconazole in two groups of neutropenic children stratified by age. Effective concentrations of itraconazole in plasma were reached quickly and maintained throughout treatment. The results indicate a trend toward higher concentrations of itraconazole in plasma in older children.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11302829      PMCID： PMC90507          DOI： 10.1128/AAC.45.5.1561-1564.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  Itraconazole oral solution versus clotrimazole troches for the treatment of oropharyngeal candidiasis in immunocompromised patients.

Authors:  P A Murray; S L Koletar; I Mallegol; J Wu; B L Moskovitz
Journal:  Clin Ther       Date:  1997 May-Jun       Impact factor: 3.393

Review 2.  Fungal infections in patients undergoing bone marrow transplantation: an approach to a rational management protocol.

Authors:  E Castagnola; B Bucci; E Montinaro; C Viscoli
Journal:  Bone Marrow Transplant       Date:  1996-11       Impact factor: 5.483

Review 3.  Invasive fungal infections in children: recent advances in diagnosis and treatment.

Authors:  T J Walsh; C Gonzalez; C A Lyman; S J Chanock; P A Pizzo
Journal:  Adv Pediatr Infect Dis       Date:  1996

4.  Determination of itraconazole in plasma and animal tissues by high-performance liquid chromatography.

Authors:  R Woestenborghs; W Lorreyne; J Heykants
Journal:  J Chromatogr       Date:  1987-01-23

5.  Determination of hydroxypropyl-beta-cyclodextrin in plasma and urine by size-exclusion chromatography with post-column complexation.

Authors:  S C Szathmary
Journal:  J Chromatogr       Date:  1989-01-27

6.  A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group.

Authors:  G R Morgenstern; A G Prentice; H G Prentice; J E Ropner; S A Schey; D W Warnock
Journal:  Br J Haematol       Date:  1999-06       Impact factor: 6.998

7.  Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels.

Authors:  M A Boogaerts; G E Verhoef; P Zachee; H Demuynck; L Verbist; K De Beule
Journal:  Mycoses       Date:  1989       Impact factor: 4.377

8.  Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children.

Authors:  L de Repentigny; J Ratelle; J M Leclerc; G Cornu; E M Sokal; P Jacqmin; K De Beule
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

9.  The efficacy of itraconazole against systemic fungal infections in neutropenic patients: a randomised comparative study with amphotericin B.

Authors:  J W van't Wout; I Novakova; C A Verhagen; W E Fibbe; B E de Pauw; J W van der Meer
Journal:  J Infect       Date:  1991-01       Impact factor: 6.072

10.  Multiple dose pharmacokinetics of an oral solution of itraconazole in patients receiving chemotherapy for acute myeloid leukaemia.

Authors:  A G Prentice; D W Warnock; S A Johnson; P C Taylor; D A Oliver
Journal:  J Antimicrob Chemother       Date:  1995-10       Impact factor: 5.790
View more
  17 in total

1.  Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants.

Authors:  Arne Simon; Mette Besuden; Sandra Vezmar; Carola Hasan; Dagmar Lampe; Sigrid Kreutzberg; Axel Glasmacher; Udo Bode; Gudrun Fleischhack
Journal:  Support Care Cancer       Date:  2006-08-30       Impact factor: 3.603

2.  Successful empirical antifungal therapy of intravenous itraconazole with pharmacokinetic evidence in pediatric cancer patients undergoing hematopoietic stem cell transplantation.

Authors:  Hyery Kim; Donghoon Shin; Hyoung Jin Kang; Kyung-Sang Yu; Ji Won Lee; Sung Jin Kim; Min Sun Kim; Eun Sun Song; Mi Kyoung Jang; June Dong Park; In-Jin Jang; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn
Journal:  Clin Drug Investig       Date:  2015-07       Impact factor: 2.859

3.  Posaconazole plasma concentrations in juvenile patients with invasive fungal infection.

Authors:  Gopal Krishna; Angela Sansone-Parsons; Monika Martinho; Bhavna Kantesaria; Lisa Pedicone
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

4.  Therapeutic penetrating keratoplasty in severe fungal keratitis using cryopreserved donor corneas.

Authors:  Y-F Yao; Y-M Zhang; P Zhou; B Zhang; W-Y Qiu; S C G Tseng
Journal:  Br J Ophthalmol       Date:  2003-05       Impact factor: 4.638

5.  Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis.

Authors:  Andreas H Groll; Lauren Wood; Maureen Roden; Diana Mickiene; Christine C Chiou; Ellen Townley; Luqman Dad; Stephen C Piscitelli; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

Review 6.  Antifungal agents in neonates: issues and recommendations.

Authors:  Benito Almirante; Dolors Rodríguez
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 7.  Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.

Authors:  Jodi M Lestner; P Brian Smith; Michael Cohen-Wolkowiez; Daniel K Benjamin; William W Hope
Journal:  Br J Clin Pharmacol       Date:  2013-06       Impact factor: 4.335

Review 8.  Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients.

Authors:  Kevin J Downes; Brian T Fisher; Nicole R Zane
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

Review 9.  Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.

Authors:  H Ruth Ashbee; Rosemary A Barnes; Elizabeth M Johnson; Malcolm D Richardson; Rebecca Gorton; William W Hope
Journal:  J Antimicrob Chemother       Date:  2013-12-29       Impact factor: 5.790

10.  Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients.

Authors:  Antonio C Arrieta; Michael Neely; J Christopher Day; Susan R Rheingold; Paul K Sue; William J Muller; Lara A Danziger-Isakov; Julie Chu; Inci Yildirim; Grace A McComsey; Haydar A Frangoul; Tempe K Chen; Victoria A Statler; William J Steinbach; Dwight E Yin; Kamal Hamed; Mark E Jones; Christopher Lademacher; Amit Desai; Kelley Micklus; Desiree Leiva Phillips; Laura L Kovanda; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2021-07-16       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.